Please login to the form below
Myovant
This page shows the latest Myovant news and features for those working in and with pharma, biotech and healthcare.
Myovant Sciences and Pfizer publish phase 3 results for endometriosis therapy
Myovant Sciences and Pfizer have published the results of the phase 3 SPIRIT 1 and SPIRIT 2 studies in The Lancet, assessing the investigational once-daily relugolix combination therapy in over ... Approximately 7.5 million premenopausal women in the US
Latest news
-
FDA approves Myovant’s oral pill Orgovyx for prostate cancer
The US Food and Drug Administration (FDA) has approved Myovant’s once-daily pill Orgovyx for prostate cancer. ... day,” said Lynn Seely, chief executive officer of Myovant Sciences.
-
Myovant preps US filing for relugolix in prostate cancer
Takeda-partnered drug had 97% response rate in advanced prostate cancer. Myovant is locked in a battle with AbbVie for women’s health applications of its GnRH inhibitor relugolix, but a ... Myovant is in a head-to-head battle with AbbVie and its rival
-
Sumitomo Dainippon goes big on biotech with $3bn Roivant deal
The five companies Sumitomo is set to take over from Roivant include Myovant, Urovant, Enzyvant, Altavant and another undisclosed spinout company. ... Although Sumitomo will gain a major stake in Urovant and Myovant (75% and 45%), the Japanese pharma
-
AbbVie files blockbuster hopeful elagolix for uterine fibroids
Will face competition from Myovant rival. AbbVie is gunning for the second indication for its new women’s health product Orilissa, hoping to add uterine fibroids to its FDA approval last ... However, AbbVie is facing some competition in the category
-
Myovant has second phase 3 trial to back its uterine fibroids drug
and bone mineral density reductions, although both Myovant and AbbVie insist the additional risk is modest. ... The big question is whether AbbVie’s marketing muscle or Myovant’s more patient-friendly dosing will win out in the jostle for market share
More from news
Approximately 6 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Sciterion
Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
